Mitochondrial Augmentation Technology (MAT) involves internalizing healthy, functional mitochondria into patient-derived cells to address mitochondrial dysfunction. Minovia has developed two generations of MAT products, studied in patients with primary mitochondrial disease in collaboration with Sheba Medical Center. In this presentation, Dr. Elad Jacoby, the treating physician, and Dr. Noa Sher, Minovia’s CSO, will discuss the promises, challenges, and clinical outcomes of this innovative therapy, providing a comprehensive review of the data to date. This session offers valuable insights for patients, families, and clinicians interested in cutting-edge mitochondrial disease therapies.
Dr. Fran Kendall of VMP Genetics discusses “Is it really Mito? When an alternative diagnosis should be considered.” Talking points include: Clinical red flags...
The annual town hall meeting is MitoAction’s way of kicking off the new year by sharing all that we have in store for the...
Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and...
